PDCD1 and lung carcinoma: In addition, ARAC has shown efficacy in another model of lung cancer (KLN-205), which is unresponsive to combination treatment with cytotoxic T-lymphocyte associated protein 4 (CTLA4) and PD-1 antibodies (142).